Sign in →

Test Code C5DCU C5-DC Acylcarnitine, Quantitative, Random, Urine

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Specimen Type

Urine


Ordering Guidance


This second-tier test is used specifically to evaluate a newborn screening elevation of glutarylcarnitine and must not be ordered with either C4U / C4 Acylcarnitine, Quantitative, Random, Urine or C5OHU / C5-OH Acylcarnitine, Quantitative, Random, Urine.

 

For general screening for metabolic disorders, see OAU / Organic Acids Screen, Random, Urine; ACRN / Acylcarnitines, Quantitative, Plasma; and AAQP / Amino Acids, Quantitative, Plasma.



Necessary Information


Include patient's age, family history, clinical condition (asymptomatic or acute episode), diet, and drug therapy information.

Specimen Required


Patient Preparation: If clinically feasible, discontinue L-carnitine supplementation at least 72 hours before specimen collection.

Supplies: Urine Tubes, 10 mL (T068)

Collection Container/Tube: Clean, plastic urine collection container

Submission Container/Tube: Plastic, 10-mL urine tube

Specimen Volume: 5 mL

Collection Instructions:

1. Collect a random urine specimen.

2. Freeze specimen immediately.


Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time
Urine Frozen (preferred) 7 days
  Refrigerated  24 hours

Reference Values

<1.54 millimoles/mole creatinine

Day(s) Performed

Monday, Wednesday, Friday

CPT Code Information

82017

Clinical Information

An isolated elevation of glutarylcarnitine (C5-DC) in plasma or newborn screening blood spots is related to a diagnosis of glutaric aciduria type 1 (GA-1), also known as glutaric acidemia type 1. GA-1 is caused by a deficiency of glutaryl-CoA dehydrogenase. Diagnostic testing by acylcarnitine analysis, including the evaluation of C5DC in urine, is helpful to determine if a patient has GA1.(1) Urinary excretion of C5-DC is a specific biochemical marker of GA-1 that appears to be elevated even in low excretors, those patients who are affected but have normal levels of glutaric acid in urine.

 

GA-1 is characterized by bilateral striatal brain injury leading to dystonia, often a result of acute neurologic crises triggered by illness. Many affected individuals also have macrocephaly. Dietary treatment and aggressive interventions during time of illness are recommended to try to prevent or minimize neurologic injury, which is most likely to occur in infancy and early childhood. Prevalence is approximately 1 in 100,000 individuals.

 

The American College of Medical Genetics and Genomics newborn screening work group published diagnostic algorithms for the follow-up of infants who had a positive newborn screening result. For more information, see the Practice Resources: ACT Sheets and Algorithms at www.acmg.net.

Report Available

2 to 5 days

Reject Due To

  All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Method Name

Flow Injection Analysis-Tandem Mass Spectrometry (FIA-MS/MS)